Daily Briefing for October 29, 2026

Show Notes

Kennedy lets doctors compound six unapproved peptides, including BPC-157

The voices on this episode are generated, and so is the script, from the day's post at Physician in the Loop. Every fact in the post links to its source.

Read the post and its sources

Get the free email briefing

Federal health officials will not take enforcement action against licensed physicians and state-licensed pharmacies that compound six unapproved peptides, including BPC-157 and TB-500, under a policy Health and Human Services posted Wednesday.

The policy requires a patient-specific prescription, bulk ingredients from an FDA-registered manufacturer with a certificate of analysis, a single active ingredient and reporting of serious adverse events to MedWatch, according to the HHS policy document. The FDA had previously advised people not to use the peptides, The Independent reported.

In other news, emergency physicians at 20 departments spent 2.4 fewer minutes on each note when they used an AI scribe, and Eli Lilly's investigational retatrutide produced more than twice the weight loss of Ozempic in a head-to-head type 2 diabetes trial.

In this episode

• HHS will let physicians and pharmacies compound BPC-157, TB-500 and four other unapproved peptides without FDA enforcement
• AI scribes cut emergency physicians' active note time 2.4 minutes across 20 departments without raising 72-hour returns
• Lilly's retatrutide beats Ozempic head to head in type 2 diabetes, with about 21% weight loss vs. 9% at 80 weeks
• Zocdoc opens appointment booking to registered AI agents as agent traffic grows nearly 30-fold since July
• Voice-guided AI makes endoscopic ultrasound exams more complete in a randomized trial but adds about 2 minutes
• Caring text messages beat support calls for suicidal adolescents at 12 months, while adults did better with calls, trial finds

What is Physician in the Loop?

How technological innovation is changing medicine for patients and the people who practice on the front lines.

Voice 1: This is Physician in the Loop, the daily briefing on AI in medicine. It's Thursday, October 29th, 2026.

Voice 1: Six unapproved peptides, including BPC-157 and TB-500, can now be compounded by physicians without the FDA stepping in, under a policy Health and Human Services posted Wednesday.

Voice 2: Any peptide, or did they name which ones?

Voice 1: Six, by name. Secretary Robert F. Kennedy Jr.’s policy covers BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500, each tied to specific routes, like Semax only intranasal and KPV only topical or oral.

Voice 2: What do compounders actually have to do to use this cover?

Voice 1: Pull the bulk ingredient from an FDA-registered manufacturer with a certificate of analysis, use a single active ingredient, label it as compounded and not for resale, and report serious adverse events and quality problems to MedWatch and to the states.

Voice 2: Does this mean the FDA now considers these things safe?

Voice 1: No. An HHS spokeswoman, Emily Hilliard, told The New York Times the policy, quote, does not grant F.D.A. approval or establish clinical safety and effectiveness. The FDA had previously advised people not to use these peptides at all.

Voice 2: So doctors get the legal room to prescribe them, and the agency still isn’t vouching for them.

Voice 1: Emergency physicians got a different kind of relief this week, from their keyboards. Across 20 emergency departments, doctors using an AI scribe cut their active note time by 2.4 minutes.

Voice 2: How many physicians, and compared against what?

Voice 1: 275 attending physicians, 3 academic and 17 community departments. Each doctor’s scribed notes were compared with their own unassisted notes, and median time in the note fell from 12.5 minutes to 10.

Voice 2: Did faster notes mean sloppier ones, more patients bouncing back?

Voice 1: The opposite, actually. Scribed notes started about 15 minutes later and ran about 14% longer, but overall completion came 6 minutes sooner, and 72-hour returns fell slightly rather than rose.

Voice 2: A scribe that saves time without hurting the one safety number anyone would worry about.

Voice 1: Lilly had a trial result of its own this week, in diabetes instead of the emergency department.

Voice 2: In a head-to-head trial against semaglutide, Lilly’s investigational drug retatrutide produced roughly twice the weight loss, at about 21% versus about 9%, at 80 weeks.

Voice 1: How big was this trial, and who was in it?

Voice 2: 1,298 adults with type 2 diabetes, all on metformin and some also on an SGLT2 inhibitor, randomized to weekly retatrutide at two doses or weekly semaglutide. The trial is called TRANSCEND-T2D-2.

Voice 1: Is this independently reviewed, or just the company’s numbers?

Voice 2: Just Lilly’s. The results haven’t been peer reviewed, and retatrutide isn’t approved anywhere yet.

Voice 1: What about people dropping out from side effects?

Voice 2: Nearly 5% and about 8% quit retatrutide over adverse events, at the two doses, compared with about 3% on semaglutide.

Voice 1: Twice the weight loss, and a bigger slice of patients who couldn’t tolerate it. That’s the trade worth watching before anyone calls this settled.

Voice 2: A different trial this week looked at suicide prevention, not weight.

Voice 1: The SPARC trial tested caring text messages against calls offering practical help, after a suicide-related visit, and the better option depended on the patient’s age.

Voice 2: What did it find for each age group?

Voice 1: Among 723 adolescents, scores on a suicidal ideation and behavior scale were similar at six months, then lower with texts at twelve months. Among 797 adults, texts actually did worse at six months, and that gap closed by twelve.

Voice 2: So doctors can’t just pick one approach and use it for everyone.

Voice 1: Right, the authors said themselves that the best follow-up may depend on age. The trial ran across 9 emergency departments and 36 primary care clinics, with 1,520 patients split between adolescents and adults.

Voice 2: A text message that helps a teenager a year out did the opposite for adults at six months, which is exactly the kind of detail a blanket follow-up protocol would miss.

Voice 1: Sources and corrections are at physicianintheloop.org, where you can sign up for the free email briefing. This briefing was read by AI voices.